key: cord-1032507-tvlq0hs9
authors: Fernandes, Guillaume; Devresse, Arnaud; Scohy, Anais; De Greef, Julien; Yombi, Jean Cyr; Belkhir, Leila; Darius, Tom; Mourad, Michel; Buemi, Antoine; Kabamba, Benoit; Goffin, Eric; Kanaan, Nada
title: Monoclonal Antibody Therapy in Kidney Transplant Recipients With Delta and Omicron Variants of SARS-CoV-2: A Single-Center Case Series
date: 2022-04-27
journal: Kidney Med
DOI: 10.1016/j.xkme.2022.100470
sha: 52f0159edb67a6d861cc7059324e492547c7c9e6
doc_id: 1032507
cord_uid: tvlq0hs9

RATIONALE & OBJECTIVE: Neutralizing monoclonal antibody treatments have shown promising preliminary results in kidney transplant recipients infected with SARS-CoV-2. However, their efficacy in kidney transplant recipients infected with Omicron variant has not been reported yet. STUDY DESIGN: Single-center retrospective study. SETTING & PARTICIPANTS: We included all consecutive kidney transplant recipients treated with monoclonal antibodies for SARS-CoV-2 infection (positive polymerase chain reaction on nasopharyngeal swab) between June 10(th) 2021 and January 14(th) 2022. Forty-seven kidney transplant recipients were included. All patients had symptoms evolving for ≤ 7 days and no oxygen therapy need at monoclonal antibody infusion. RESULTS: Symptoms at diagnosis were mainly cough (n=25 [53%]) and fever (n=15 [32%]). Eighty-three percent of the cohort (n=39) had been vaccinated with at least 2 doses before infection, of whom 77% (n=30) had demonstrated a vaccine-induced humoral response. They were treated with either casirivimab-imdevimab (n= 16 [34%]) or sotrovimab (n= 31 [66%]) a median of 2 (ranges 0-6) days after the onset of symptoms. Except for one mild allergic reaction during casirivimab-imdevimab infusion, no side effects were reported. Median viral loads at admission (day 0) and 7 days after mAb infusion were 2,110,027 (ranges 1000-153,798,962) copies/mL and 1,000 (ranges 0-10,000,000) copies/mL, respectively. Genotypes were available for 22 kidney transplant recipients (47%). Omicron, Delta, and Gamma variants were identified in 13 (59%), 8 (36%), 1 (5%) patients, respectively. In kidney transplant recipients infected with Omicron variant, the median viral loads at day 0 and day 7 were 752,789 (ranges 4000-12,859,300) copies/mL and 1,353 (ranges 0-1,211,163) copies/mL, respectively. Two kidney transplant recipients required hospitalization immediately after sotrovimab perfusion for oxygen therapy that was weaned in 3 days allowing patients’ discharge. None were admitted to the intensive care unit or died. LIMITATIONS: Small sample-size, no control group. CONCLUSIONS: Neutralizing monoclonal antibody therapy is associated with positive outcomes in kidney transplant recipients with mild COVID-19, including those infected with the Omicron variant.

As of January 2022, more than 356,000,000 cases and 5,600,000 deaths have been reported by the World Health Organization due to COVID-19 pandemic and the numbers continue to rise. 1 Solid organ transplant recipients-including kidney transplant recipients were recognized early as a particularly vulnerable population to SARS-CoV-2 infection with increased mortality rates around 20-30%. 2, 3 These excess deaths are most likely triggered by the maintenance immunosuppressive treatments received to prevent graft rejection 4 and the co-morbidities affecting kidney transplant recipients. 5, 6 Since the onset of the outbreak, an unprecedented rapid development of therapeutic options occurred aiming to improve the outcome of patients infected with COVID-19. Among them vaccines have proven to be efficacious in reducing the risk of both severe disease and mortality in the general population. 7 Unfortunately, emerging evidence has revealed that kidney transplant recipients actually display a reduction in vaccine-induced humoral responses. 8 Moreover, the clinical benefit of vaccine to protect against severe COVID-19 has appeared lower in solid organ transplant recipients compared to the general population. 9 Taken together, these data suggest that alternative strategies are required for kidney transplant recipients. 10 Among them, neutralizing monoclonal antibody therapy deserves consideration. Indeed, casirivimab-imdevimab 11 and sotrovimab 12 were recently reported to be safe and effective in reducing a composite endpoint combining hospitalization and mortality in two phase 3 placebo controlled trials including immunocompetent patients infected with SARS-CoV-2 at risk of progression.

Unfortunately, kidney transplant recipients were excluded from the studies. Nevertheless, we and others [13] [14] [15] [16] [17] 

Soon after the onset of the outbreak, all kidney transplant recipients were informed to contact our center in case of possible SARS-CoV-2 infection (because of symptoms or high-risk contact). Since the availability of monoclonal antibody therapy in This study was conducted with the approval of our institutional ethics review board (2021/12NOV/470; B403/). The need for informed consent was waived due to deidentified information.

Patients were given monoclonal antibodies intravenously in our COVID-19 unit before being discharged after a 2-hour surveillance. The study was conducted from June (no need for oxygen) transplanted within the month, the immunosuppression regimen is not modified.

The vaccine-induced humoral response was measured using an immunoassay 

Forty-seven kidney transplant recipients infected with SARS-CoV-2 met the criteria to receive neutralizing monoclonal antibody treatment in our center.

As summarized in Table 1 

Most common symptoms were cough and fever (53% Figure 1 ).

Median viral loads at diagnosis were 2,110,027 (ranges 1000-153,798,962) and 752,789 (ranges 4000-12,859,300) copies/mL for the all cohort and the Omicron variant cohort, respectively (Table 2, Figure 2 ).

At day 0, the antimetabolite drug was interrupted or decreased by 50% in 34 (83%) and 6 (15%) patients, respectively. The dose was unchanged in one patient who had been transplanted 22 days prior infection.

Monoclonal antibodies were given immediately after diagnosis, a median time of 2 (ranges 0-6) days after symptoms onset.

Casirivimab/imdevimab was administered in the first 16 patients (34%). One Immediately after monoclonal antibody perfusion, two patients required hospitalization for oxygen therapy that was weaned in 3 days allowing patients' discharge. Both patients had received two doses of mRNA vaccine before infection but did not exhibit a humoral response. Genotype was not available for them but the infection occurred during the Delta-prevalent SARS-CoV-2 wave in Belgium) and they were both treated with sotrovimab.

One patient was infected in the first month (22 days) after kidney transplantation. No patient required further hospital readmission. None was admitted in intensive care unit (ICU) or died during the study period.

We herein report reassuring data regarding both the efficacy and safety of neutralizing monoclonal antibody treatment use in kidney transplant recipients with mild to moderate COVID-19 (with no need for oxygen therapy). Indeed, out of the included 47 patients, only two (4%) required short hospitalization for oxygen supply after monoclonal antibody treatment and none died or required ICU admission within a 30-day follow-up time. These results are in line with previous observations. [13] [14] [15] [16] [17] Moreover, the 30-day hospitalization rate after monoclonal antibody infusion in our cohort seems lower than those reported in two recent case-series (8.7% and 15%, respectively 24, 25 ) .

No major side effects were observed. Interestingly, the use of sotrovimab in infected kidney transplant recipients has been poorly reported so far. In this study, we provide reassuring data as 66% of our cohort was treated with sotrovimab with no safety concerns. However, the only two patients who needed hospitalization were treated with sotrovimab. They became hypoxic soon after monoclonal antibody infusion. Although a direct side effect of monoclonal antibody therapy cannot be totally excluded, oxygen therapy was weaned after three days only, which seems like a long period for allergy. In our opinion, these two seronegative patients had infection already too advanced for the monoclonal antibody therapy to prevent hospitalization, but their infusion most likely participated in the rapid recovery. 26 Both patients were quickly discharged and did not require rehospitalization. 

Our study has limitations. First, its retrospective design makes it subject to collection bias. Second, the sample size is small. Third, the rate of unavailable genotypes is high (53%). However, systematic genotype assessment was no longer performed in our center during a period of time when the Delta variant SARS-CoV-2 was highly prevalent in our country and was resumed when Omicron variant emerged in Belgium.

Consequently, it is highly plausible that a vast majority of unavailable genotypes in our study were actually Delta variants and that we did not miss any Omicron variant. Fourth, we have used Casirivimab-Indevimab and Sotrovimab as monoclonal antibody therapies. Interestingly both study periods occurred before Omicron wave onset. 24, 25 In conclusion, our study provides reassuring data about the efficacy and safety of neutralizing monoclonal antibody treatment in kidney transplant recipients with mild COVID-19, including those infected with the Omicron variant SARS-CoV-2. Larger controlled studies are required to confirm our observations.

Authors' Full Names and Academic Degrees: Guillaume Fernandes, MD 1 *, Arnaud 

COVID-19) Dashboard (Retrieved 2022

Factors associated with COVID-19-related death using OpenSAFELY

Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe

COVID-19 related mortality in kidney transplant and hemodialysis patients: a comparative, prospective registry based study

Outcomes of COVID-19 in Solid Organ Transplant Recipients: A Propensity-matched Analysis of a Large Research Network

Immunosuppression and SARS-CoV-2 Infection in Kidney Transplant Recipients

Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2

COVID-19 vaccination in kidney transplant recipients

Real-world Effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S Vaccines Against SARS-CoV-2 in Solid Organ and Islet Transplant Recipients

Current vaccine strategies against SARS_CoV-2 only poorly protect kidney transplant recipients

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Monoclonal Antibody Therapy for SARS-CoV-2 Infection in Kidney Transplant Recipients: A Case Series From Belgium

Preemptive Antibody Therapy for Vaccine Breakthrough SARS-CoV-2 Infection in Immunocompromised Patients

Anti-SARS-Cov-2 Monoclonal Antibodies in Solid-Organ-Transplant Patients

Organ transplant patients, COVID-19, and neutralizing monoclonal antibodies: The glass is half full

Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy

An infectious SARS-CoV-2

Omicron virus escapes neutralization by therapeutic monoclonal antibodies

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement

CLINICAL GUIDANCE FOR ADULTS WITH SUSPECTED OR CONFIRMED COVID-19 IN BELGIUM

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients

Use of anti-spike monoclonal antibodies in kidney transplant recipients with COVID-19: Efficacy, ethnic and racial disparities

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

Cov antibody combination to prevent COVID-19 infection in kidney transplant recipient without detectable antibody response to optimal vaccine scheme

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study

SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance

BAU/mL, median, (ranges)

Abbreviations: eGFR, estimated glomerular filtration rate

RBD, receptor-binding domain ; Tac, tacrolimus. *One patient received one dose of the

Percentages were calculated among vaccinated patients (at least two doses, n=39)

 Table 2: Characteristics at admission for monoclonal antibody treatment  Characteristics  Total cohort  n=47  Symptoms Fever, n (%) 15 (32%) Cough, n (%) 25 (53%) Shortness of breath, n (%) 3 (6%) Diarrhea, n (%) 7 (15%) SARS-CoV-2 viral load* Day 0, copies/mL, median (ranges)** 2,110,027 (1,000-153,798,962) Day 7, copies/mL, median (ranges)*** 1,000 (0-10,000,000)

Casirivimab-imdevimab, n (%) 16 (34%) Sotrovimab, n (%) 31 (66%)

Delta, n (%) 8 (17%) Omicron, n (%) 13 (28%) Gamma, n (%) 1 (2%) Not available, n (%) 25 (53%) *Polymerase chain-reaction **Day of monoclonal antibody treatment ***Seven to eight days after treatment